Cadrenal raises $3M upfront in placement that could reach $8.8M
What's the deal? Cadrenal TherapeuticsDealroom has a profile for this one. Try Dealroom → (Nasdaq: CVKD) has signed a definitive agreement for a private placement expected to raise $3 million in upfront gross proceeds.
The deal covers 960,000 common shares, or pre-funded warrants, priced at $3.125 each, sold to a single institutional investor.
It also includes series C-1 and C-2 warrants for up to 1,920,000 additional shares, exercisable at $3.00 each. If all warrants are exercised for cash, total gross proceeds reach about $8.8 million.
Why now? The clinical-stage biotech needs cash to fund its pipeline.
Net proceeds should extend its runway into the first quarter of 2027, and, with full warrant exercise, into the second half of that year.
The money supports partnering efforts for tecarfarin in Kawasaki Disease and CAD-1005 in CSA-AKI and HIT.
What could go wrong? The extra $5.8 million depends on investors fully exercising their warrants for cash — far from guaranteed.
Series C-1 warrants also hinge on future stockholder approval and registration becoming effective.
The issuance of up to 2,880,000 shares implies dilution for existing holders, and placement agent fees will reduce net cash received.
The signal: Cadrenal is an early-stage cardiorenal specialist whose lead asset, tecarfarin, carries orphan designation — a profile that leaves it dependent on partnering deals and dilutive raises rather than product revenue. Structuring most of this round through warrants lets it stretch a thin cash position into 2027 while deferring the bulk of the funding to a share price it hopes to defend.
Read more: StockTitan
Image credit: gemmerich
